ANI launched its first injectable drug for Treating Tachycardia

ANI Pharmaceuticals Inc. ("ANI") recently released details of 50 mg/mL Bretylium Tosylate Injection USP.  Bretylium Tosylate is anapproved class III antiarrhythmic drug for treating ventricular fibrillation ventricular arrhythmias.As per the data provided by IQVIA,ANI reports that the annual U.S. antiarrhythmic market is estimatedto be about $915 million.Off-hospital cardiac arrests (OHCAs) in the United States have a recorded occurrence of 395,000 incidents per year, while cardiac arrests in-hospital (IHCAs) is estimated at 200,000 per year.Bretylium Tosylate is widely placed on crash carts as a standard drug before its discontinuation. ANI in its report stated that, the U.S. has about 180,000 crash carts and will take two or four vials to treat the typical patient.

Arthur S. Przybyl, ANI's President and CEO stated, "We are excited to launch this important cardiac drug and provide physicians with another valuable therapy to treat patients with ventricular arrhythmias.”ANI launched its first injectable drug and the second hospital-based product that demonstrate its commitment to diversify its market portfolio through innovative formulations. Bretylium Tosylate is a successful medication during advanced cardiac life support for acute ventricular fibrillation and tachycardia.